Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial

CALGARY, ALBERTA--(Marketwire - March 31, 2010) - Stem Cell Therapeutics Corp. (“SCT” or the “Company”) (TSX VENTURE: SSS) announced today that it closed patient enrollment of the modified Phase IIb stroke trial on March 31st, 2010 and will analyze the data as they become available. Using a modified statistical approach the Company will analyze its trial data using the 96 patients that were enrolled.

Dr. Alan Moore, President and CEO, commented as follows:

“The modified REGENESIS-LED Phase IIb stroke trial enrolled 96 patients in six months which is a tremendous achievement. Despite our best recruitment efforts, however, we have not recruited any additional North America patients. The last patient in the trial was recruited at the end of January 2010. Using an alternate method of data analysis, with a proven track record (used in one of t-PA’s pivotal phase III studies) will allow us to achieve our endpoint with fewer patients while staying on track with our previously reported time-line. We look forward to receiving the results of this clinical trial for the treatment of stroke patients with NTx®-265.”

With the modified Phase IIb stroke trial closed, SCT anticipates to complete patient 90 day endpoint assessments by the end of April 2010 with data analysis to follow soon after.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair brain and nerve function lost due to disease or injury. The Company’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.